Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in Recurrent or Metastatic Cervical Cancer
NCT05557565Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in Cervical Cancer (CC), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05557565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557565.